Clofarabine, a nucleoside analogue for treatment of relapsed leukemia, is 50-60% excreted in urine. Clofarabine has not been studied in patients on hemodialysis. We measured levels in one patient in acute renal failure. Prior to dialysis, 43 hr after a 40 mg/m(2) infusion, plasma concentration was 139 ng/ml. One hour after beginning hemodialysis, a 20 mg/m(2) infusion began. Plasma concentrations were 84.2, 81.1, and 88.0 ng/ml while the dialysis and clofarabine infusion occurred simultaneously. Post-dialysis, while the clofarabine was still infusing, the level was 95.8 ng/ml. Hemodialysis does decrease clofarabine levels, but given its large volume distribution, hemodialysis may not be effective for clofarabine overdose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.22458 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood
January 2025
Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Prizloncabtagene autoleucel (prizlon-cel), a novel bispecific chimeric antigen receptor (CAR) T-cell, targets and eliminates CD19/CD20 positive tumor cells. This phase 1, open-label study investigated the safety and efficacy of prizlon-cel in patients with relapsed/refractory B-cell non-Hodgkin Lymphoma (r/r B-NHL). Patients with CD19 and/or CD20-positive r/r B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2/d; fludarabine: 30 mg/m2/d) followed by an intravenous dose of prizlon-cel.
View Article and Find Full Text PDFOne-Day Brentuximab-Bendamustine (120 mg/m2) Every 21 Days is a Feasible, Safe and Effective Treatment for Relapsed/Refractory Hodgkin Lymphoma.
Hematol Oncol
January 2025
Département d'Hématologie, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Brentuximab vedotin (BV)-bendamustine (90 or 120 mg/m2 day 1 and 2) every 28 days is an effective treatment for relapsed/refractory Hodgkin lymphoma (R/R HL) but associated to high toxicity especially for elderly patients. We conducted in St Louis Hospital, Paris, between 2015 and 2021 a retrospective single-center analysis of 44 patients with R/R HL treated with one-day BV-bendamustine (120 mg/m2) every 21 days. Sixteen percent of patients were ≥ 60 years old (yo).
View Article and Find Full Text PDFBackground: Idiopathic retroperitoneal fibrosis is characterized by the development of inflammatory infiltrates with marked fibrosis along the large retroperitoneal vessels. Rituximab in combination with glucocorticoids constitute an effective therapy, but the responses are not long-lasting. In other similar situations, addition of cyclophosphamide to the combination achieved longer and deeper responses.
View Article and Find Full Text PDFLow-Dose Rituximab in the Treatment of Primary Membranous Nephropathy - A Systematic Review and Meta-Analysis.
G Ital Nefrol
October 2024
Department of Nephrology, SRM Medical College Hospital and Research Centre, Kattankulathur, Tamil Nadu, India-603203.
Article Synopsis
- - Rituximab (RTX) shows potential as a treatment for idiopathic membranous nephropathy (IMN), but its high cost and severe side effects have led to exploring low-dose RTX as a viable option.
- - A systematic review analyzed 16 studies that evaluated the effects of low-dose RTX on adult IMN patients, with main outcomes focused on complete and partial response rates and secondary effects on kidney function and protein levels.
- - Results indicated that low-dose RTX treatments resulted in significant rates of complete remission, improved serum albumin levels, and reduced protein-creatinine ratio, though a concerning trend of lower estimated glomerular filtration rate (eGFR) was observed post-treatment in second-line therapy patients
Rituximab in lupus anticoagulant hypoprothrombinemia syndrome: A case report.
Lupus
December 2024
Department of Cardiothoracic and Vascular Sciences, Thrombosis Centre, University of Padua School of Medicine, Padua, Italy.
Article Synopsis
- Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare autoimmune disorder linked to antiphospholipid syndrome, which causes severe bleeding due to low prothrombin levels, as illustrated by a case study of a 34-year-old woman with heavy menstrual bleeding and related complications.
- The patient underwent extensive testing, revealing deficiencies in factors II and IX, leading to the initiation of immunosuppressive treatment with Rituximab and hormonal therapy with desogestrel to manage antibody levels and reduce bleeding.
- After one year of treatment, the patient achieved complete remission, with restored levels of prothrombin and factor IX while showing reduced antibody
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!